Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa
Primary Purpose
Placenta Previa
Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Placebo
Nifedipine
Sponsored by
About this trial
This is an interventional treatment trial for Placenta Previa
Eligibility Criteria
Inclusion Criteria:
- Placenta previa is diagnosed when the lowest placental edge is located within 5 cm of the internal os at ultrasonography
- Placenta previa may be symptomatic with at least one episode of bleeding
- Estimated gestational age within 24 to 34 weeks
- Maternal age > 18 years
- Informed consent after received an explanation of the study and an information sheet
- Social affiliation
Exclusion Criteria:
- Premature rupture of membranes
- Severe bleeding requiring an immediate termination of pregnancy
- Abnormal fetal heart rates requiring an immediate termination of pregnancy
- Intrauterine fetal death
- Pre-eclampsia, chorioamnionitis, liver disease, severe chronic renal disease, heart disease
- Abruptio placentae
- Nifedipine sensibility
- Drugs interaction with nifedipine
Sites / Locations
- University Hospital Rouen
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
A
B
Arm Description
Placebo three times daily
20 mg of slow-release Nifedipine three times daily
Outcomes
Primary Outcome Measures
Prolongation of pregnancy
Secondary Outcome Measures
Maternal outcomes i.e number episodes of bleeding, amount of bleeding, number of blood transfusion required
Full Information
NCT ID
NCT00620724
First Posted
January 28, 2008
Last Updated
July 9, 2014
Sponsor
University Hospital, Rouen
1. Study Identification
Unique Protocol Identification Number
NCT00620724
Brief Title
Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa
Official Title
Maintenance Oral Nifedipine for Management of Symptomatic Placenta Previa : A Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
September 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Rouen
4. Oversight
5. Study Description
Brief Summary
The objective of our study is to determine the clinical utility related to the maintenance oral nifedipine therapy in patients with symptomatic placenta previa. This study is a prospective, randomized controlled trial with the inclusion, after 24 weeks gestation, of hospitalized patients with symptomatic placenta praevia. All patients may initially receive oral nifedipine therapy with steroid prophylaxis for 48 hours. After then, patients are randomly assigned to receive either oral nifedipine (20 mg every 8 hours) or placebo (one every 8 hours) until 37 weeks of gestation.
The primary outcome for the trial is the length of pregnancy in days after the enrollment. A sample size calculation is designed to detect at least a 14 -day difference in time gained in patients with maintenance oral nifedipine therapy. A sample size of about 52 patients per group would have a 80 % chance of detecting this difference at the 5 % level of significance.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Placenta Previa
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
109 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Placebo Comparator
Arm Description
Placebo three times daily
Arm Title
B
Arm Type
Experimental
Arm Description
20 mg of slow-release Nifedipine three times daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo three times daily
Intervention Type
Drug
Intervention Name(s)
Nifedipine
Intervention Description
20 mg of slow-release Nifedipine three times daily
Primary Outcome Measure Information:
Title
Prolongation of pregnancy
Time Frame
From allocation to the delivery
Secondary Outcome Measure Information:
Title
Maternal outcomes i.e number episodes of bleeding, amount of bleeding, number of blood transfusion required
Time Frame
At the end of the study
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Placenta previa is diagnosed when the lowest placental edge is located within 5 cm of the internal os at ultrasonography
Placenta previa may be symptomatic with at least one episode of bleeding
Estimated gestational age within 24 to 34 weeks
Maternal age > 18 years
Informed consent after received an explanation of the study and an information sheet
Social affiliation
Exclusion Criteria:
Premature rupture of membranes
Severe bleeding requiring an immediate termination of pregnancy
Abnormal fetal heart rates requiring an immediate termination of pregnancy
Intrauterine fetal death
Pre-eclampsia, chorioamnionitis, liver disease, severe chronic renal disease, heart disease
Abruptio placentae
Nifedipine sensibility
Drugs interaction with nifedipine
Facility Information:
Facility Name
University Hospital Rouen
City
Rouen
ZIP/Postal Code
76031
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
35947046
Citation
Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2.
Results Reference
derived
PubMed Identifier
28333939
Citation
Verspyck E, de Vienne C, Muszynski C, Bubenheim M, Chanavaz-Lacheray I, Dreyfus M, Deruelle P, Benichou J. Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial. PLoS One. 2017 Mar 23;12(3):e0173717. doi: 10.1371/journal.pone.0173717. eCollection 2017.
Results Reference
derived
Learn more about this trial
Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa
We'll reach out to this number within 24 hrs